Publication of clinical trials supporting successful new drug applications: a literature analysis
about
Reporting bias in medical research - a narrative reviewPeginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis CSeventy-five trials and eleven systematic reviews a day: how will we ever keep up?Outcome reporting among drug trials registered in ClinicalTrials.govPublication of NIH funded trials registered in ClinicalTrials.gov: cross sectional analysisClinical trial registration, reporting, publication and FDAAA compliance: a cross-sectional analysis and ranking of new drugs approved by the FDA in 2012Toward an Open-Access Global Database for Mapping, Control, and Surveillance of Neglected Tropical DiseasesTrial publication after registration in ClinicalTrials.Gov: a cross-sectional analysisPublication bias in antipsychotic trials: an analysis of efficacy comparing the published literature to the US Food and Drug Administration databaseImpact of reporting bias in network meta-analysis of antidepressant placebo-controlled trialsPositive outcomes influence the rate and time to publication, but not the impact factor of publications of clinical trial resultsQuality and quantity of information in summary basis of decision documents issued by health CanadaMoving forward from rhBMP-2: open science and data sharingCompleteness and changes in registered data and reporting bias of randomized controlled trials in ICMJE journals after trial registration policyTowards agreement on best practice for publishing raw clinical trial dataPublication delay of randomized trials on 2009 influenza A (H1N1) vaccination.Bladder cancer--the neglected tumor: a descriptive analysis of publications referenced in MEDLINE and data from the register ClinicalTrials.gov.Extent of publication bias in different categories of research cohorts: a meta-analysis of empirical studies.Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for TerminationBias, spin, and misreporting: time for full access to trial protocols and results.The financing of drug trials by pharmaceutical companies and its consequences: part 2: a qualitative, systematic review of the literature on possible influences on authorship, access to trial data, and trial registration and publication.A systematic review of duloxetine and venlafaxine in major depression, including unpublished data.Challenges in conducting clinical trials in children: approaches for improving performanceAnalysis of pediatric clinical drug trials for neuropsychiatric conditionsPeginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: systematic review of randomized trials.Deficiencies in the transfer and availability of clinical trials evidence: a review of existing systems and standards.How does under-reporting of negative and inconclusive results affect the false-positive rate in meta-analysis? A simulation study.Discontinuation and non-publication of surgical randomised controlled trials: observational study.Publication of pivotal efficacy trials for novel therapeutic agents approved between 2005 and 2011: a cross-sectional studyPublication bias in meta-analyses from the Cochrane Database of Systematic Reviews.The Use of Registries to Improve Cancer Treatment: A National Database for Patients Treated with Interleukin-2 (IL-2).Clinicaltrials.gov: Is the Glass Half Full?Focusing the spotlight on lack of access to health information.Publication bias in recent meta-analyses.Incorporating evidence-based medicine into resident education: a CORD survey of faculty and resident expectationsOccurrence and determinants of selective reporting of clinical drug trials: design of an inception cohort studyClinicalTrials.gov and Drugs@FDA: A Comparison of Results Reporting for New Drug Approval Trials.Pediatric versus adult drug trials for conditions with high pediatric disease burden.Has the rising placebo response impacted antidepressant clinical trial outcome? Data from the US Food and Drug Administration 1987-2013.Protections for clinical trials in low and middle income countries need strengthening not weakening
P2860
Q21203744-2390A689-79CB-47FB-812C-6F41FD5B26FDQ24200197-65B4B801-DB7F-4C36-8D19-E7420791C245Q24288768-DB4B4EDB-697C-4475-ABBE-5EBC901DDB3EQ24289273-C725ABC8-F9F0-445B-85A6-3F74DF49C8F4Q24718169-32202EE9-F113-4846-B69A-A2B22D6F8A10Q26777323-38D178BF-ECB9-4C62-ADF8-5E48365720DAQ27826358-818CA950-FFB5-4E38-B292-3BCA6301EEB7Q28476002-E10E1FFD-B48C-4423-BF1D-87D9173D35C9Q28481584-25042C2B-0B5F-4528-87FA-BADC951096E6Q28482475-C96FAE19-90DA-494D-936A-BE42DDD1135DQ28485388-909B0125-D0C3-4AA3-86DF-57B88D51FE51Q28541228-29549CD0-47F7-4F02-A936-267C24CD8288Q28660290-E1011DDA-1F57-4BBE-90E0-C69CB962E55BQ28744662-91827557-0E99-46B8-B792-24E03F628432Q28754920-6CD69EE2-C343-446A-9E64-2446B7334077Q30410554-7814D404-04B1-4E85-8D55-7AA2270D4989Q30683510-97D6D3C8-A98A-4A7E-A603-106B84C6F7D4Q30920608-950F7AD5-9170-44D9-BA7D-E9297FAC6B50Q30958675-B8AE3D5B-E733-4CFD-9D05-9B3D6B2984ADQ33391502-50F83399-E597-4F43-9AD5-873E5EAE34FAQ33583631-75F6CF43-6FC0-42D1-A533-96C8587E4748Q33689953-068BF659-3F67-4E2C-B5BC-E8F792A4A3BDQ33717140-4E408977-2775-466F-BC13-5EF8F8BE0D70Q33819758-0161E7C0-6E8C-4ABC-8502-6D85659836FCQ34100819-7EF9C185-30BB-489F-8871-06DD188FFFDBQ34402803-CC534D4A-4DEE-4CFB-9E80-F9DBB9A36871Q34435723-FBF9C9BA-A4AE-4721-8E4A-6E67FBD7B487Q34452911-0524EE6D-D94D-4C2D-8BA4-59C02565E46CQ34457418-B3D84E35-0E39-4634-BCA4-8E7415633201Q34476958-24BA31FF-D266-4A56-A6FF-635843E837F8Q34608796-D7D3CA48-33F1-43C5-BA31-2BC6A8C89A57Q34612897-1280ACAF-1226-4275-B24E-921ADBA8BBE9Q34699642-B7E7A8B3-E9F5-438B-9CA7-0CB2AB74B6F0Q35074341-86AD8B4D-2AB0-4701-AD4C-89B3645BF80BQ35561026-EB58982F-62D3-4A09-8F68-DDE2D47EE25EQ35844255-58F4DF2C-3B5F-4C69-B3D2-C752216A8798Q36050268-BA4685FA-BA14-430F-963A-61A9C2E965E2Q36128904-F489B928-96B8-48AF-8611-DA804ED4C2BEQ36370168-5888886B-EA50-40E1-A456-3EED19373E99Q36396604-870438E7-EF17-4E7C-B1FA-F334576517F5
P2860
Publication of clinical trials supporting successful new drug applications: a literature analysis
description
2008 nî lūn-bûn
@nan
2008 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Publication of clinical trials ...... cations: a literature analysis
@ast
Publication of clinical trials ...... cations: a literature analysis
@en
Publication of clinical trials ...... cations: a literature analysis
@en-gb
Publication of clinical trials ...... cations: a literature analysis
@nl
type
label
Publication of clinical trials ...... cations: a literature analysis
@ast
Publication of clinical trials ...... cations: a literature analysis
@en
Publication of clinical trials ...... cations: a literature analysis
@en-gb
Publication of clinical trials ...... cations: a literature analysis
@nl
altLabel
Publication of Clinical Trials ...... cations: A Literature Analysis
@en
prefLabel
Publication of clinical trials ...... cations: a literature analysis
@ast
Publication of clinical trials ...... cations: a literature analysis
@en
Publication of clinical trials ...... cations: a literature analysis
@en-gb
Publication of clinical trials ...... cations: a literature analysis
@nl
P2860
P3181
P1433
P1476
Publication of clinical trials ...... cations: a literature analysis
@en
P2093
Peter Bacchetti
P2860
P3181
P356
10.1371/JOURNAL.PMED.0050191
P407
P50
P577
2008-09-23T00:00:00Z